Clinical Research Directory
Browse clinical research sites, groups, and studies.
PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Sponsor: Celularity Incorporated
Summary
This Phase 2a study evaluated the efficacy, safety, and tolerability of intravenous human placenta-derived cells (PDA001) compared with placebo in adults with moderate-to-severe Crohn's disease. Three PDA001 dose levels were evaluated.
Official title: A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intravenous PDA001 for the Treatment of Adults With Moderate-to-Severe Crohn's Disease
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2010-08
Completion Date
2014-04
Last Updated
2026-07-07
Healthy Volunteers
No
Conditions
Interventions
Human Placenta-Derived Cells PDA001 Intravenous Infusion
Vehicle Control
Locations (13)
Cedars Sinai Medical Center
Los Angeles, California, United States
University of California, Irvine
Orange, California, United States
Yale School of Medicine Digestive Diseases
New Haven, Connecticut, United States
University of Florida
Gainesville, Florida, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Mt Sinai Hospital
New York, New York, United States
Rochester General Hospital
Rochester, New York, United States
Stony Brook University
Stony Brook, New York, United States
Case Western Reserve University
Cleveland, Ohio, United States
Vanderbilt University
Nashville, Tennessee, United States
Baylor College of Medicine
Houston, Texas, United States
McGuire VA Medical Center
Richmond, Virginia, United States